0001104659-17-041905.txt : 20170627
0001104659-17-041905.hdr.sgml : 20170627
20170627215606
ACCESSION NUMBER: 0001104659-17-041905
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170623
FILED AS OF DATE: 20170627
DATE AS OF CHANGE: 20170627
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics Plc
CENTRAL INDEX KEY: 0001703287
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: 6108166640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Plc
DATE OF NAME CHANGE: 20170407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Khuong Chau Quang
CENTRAL INDEX KEY: 0001609405
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38132
FILM NUMBER: 17933633
MAIL ADDRESS:
STREET 1: C/O ORBIMED ADVISORS
STREET 2: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
4
1
a4.xml
4
X0306
4
2017-06-23
0
0001703287
Nabriva Therapeutics Plc
NBRV
0001609405
Khuong Chau Quang
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA
PA
19406
1
0
1
0
Ordinary Shares
2017-06-23
5
J
0
E
1677940
0
A
1677940
I
See footnotes
Ordinary Shares
2017-06-23
5
J
0
E
2241660
0
A
2241660
I
See footnotes
Stock Option
2017-06-23
5
J
0
E
10100
0
A
2026-08-25
Ordinary Shares
10100
10100
D
Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
These shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed Capital GP V LLC ("GP V"), which is the sole general partner of OPI V, which is the majority member of OrbiMed Private Investments V Cooperatief U.A. ("OPI V Cooperatief"), which is the sole shareholder of OrbiMed Private Investments V-NB B.V. ("OPI V- NB"). OPI V and OPI V-NB hold ADSs and Common Shares, respectively, as described herein. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of Advisors and owns a controlling interest in Advisors.
The Reporting Person, an employee of Advisors, has been designated by Advisors to serve on the issuer's board of directors and disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") except to the extent of his pecuniary interest therein, if any. This report on Form 3 shall not be deemed any admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purpose.
These shares are held of record by OPI V-NB.
The exercise price is 6.634 Euro.
This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.
/s/ Gary L. Sender, by power of attorney
2017-06-27